Entresto's Effect on Electrolytes
Entresto (sacubitril/valsartan) causes hyperkalemia in approximately 12-18% of patients and hypotension in 18% of patients, while having minimal to no clinically significant effect on serum sodium levels. 1
Potassium Effects
Incidence and Magnitude
- Hyperkalemia (K+ >5.5 mEq/L) occurs in approximately 16-18% of patients treated with Entresto, which is similar to or slightly lower than enalapril (16%) and valsartan alone (20%) 1
- In the PARADIGM-HF trial, hyperkalemia rates were comparable between Entresto and enalapril (12% vs 14% as adverse reactions) 1
- Severe hyperkalemia (K+ >6.0 mEq/L) is actually LESS common with Entresto than with ACE inhibitors, particularly when combined with mineralocorticoid receptor antagonists (MRAs) 2
Clinical Context
Entresto is listed among drugs that decrease potassium excretion and can cause hyperkalemia 3. However, the neprilysin inhibition component appears to provide a protective effect against severe hyperkalemia compared to traditional RAAS inhibitors. When patients on MRAs were switched to Entresto, severe hyperkalemia occurred at 2.3 per 100 patient-years versus 3.3 per 100 patient-years with enalapril 2.
Special Populations
In anuric hemodialysis patients, Entresto increased mean serum potassium from 4.84 to 5.04 mmol/L over 6 months, but severe hyperkalemia remained uncommon (4.2% at 6 months), suggesting relative safety even in this high-risk population 4.
Sodium Effects
Minimal Clinical Impact
Serum sodium levels are NOT significantly affected by Entresto in most patients 5. Despite the drug's natriuretic effects (increased sodium excretion), this does not translate to clinically significant hyponatremia in the majority of cases.
Rare Hyponatremia
While case reports of Entresto-induced hyponatremia exist 6, this is uncommon. The drug actually increases natriuresis and diuresis acutely (first 24 hours), particularly in salt-sensitive hypertension, but this effect diminishes by day 28 5.
Blood Pressure Effects
Hypotension is the most common electrolyte-related adverse effect, occurring in 18% of patients (compared to 12% with enalapril) 1. This manifests as:
- Orthostasis in 2.1% of patients
- Falls in 1.9% of patients
- Dizziness in 6% of patients
Monitoring Algorithm
Check potassium and creatinine:
- At baseline
- Within 1-2 weeks of initiation
- After each dose uptitration
- At 1,3,6, and 12 months, then periodically
Hold or reduce dose if:
- K+ >5.5 mEq/L (consider holding)
- K+ >6.0 mEq/L (hold and address)
- Symptomatic hypotension
- Creatinine increase >50% from baseline
Drug Interactions Increasing Hyperkalemia Risk
Concomitant use with these agents increases hyperkalemia risk 1:
- Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)
- Potassium supplements
- Salt substitutes containing potassium
- NSAIDs
- Other RAAS inhibitors (contraindicated with ACE inhibitors; avoid with other ARBs)
Key Clinical Pitfalls
- Don't avoid Entresto solely due to hyperkalemia concerns - the risk is similar to or lower than traditional RAAS inhibitors, and the mortality benefit is substantial
- The neprilysin inhibition component actually provides relative protection against severe hyperkalemia compared to ACE inhibitors, especially when combined with MRAs 2
- Hyponatremia is rare despite increased natriuresis - don't over-monitor sodium unless clinically indicated
- Hypotension is more common than electrolyte abnormalities - counsel patients about orthostatic symptoms and falls risk